Inhibition of mTOR in carcinoid tumors (Q38034141)

27 August 2017

title

Inhibition of mTOR in carcinoid tumors (English)

1 reference

27 August 2017

1 reference

Simona Grozinsky-Glasberg

series ordinal

1

1 reference

27 August 2017

Marianne Pavel

series ordinal

2

1 reference

27 August 2017

publication date

12 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

7

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

189-195

1 reference

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Recent advances in the protein kinase B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

90Y-edotreotide for metastatic carcinoid refractory to octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-012-0225-X

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22886906

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22886906

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-012-0225-X

1 reference

Dimensions Publication ID

27 August 2017

1002720060

0 references

1 reference